IMPRESSION HEALTHCARE LIMITED(IHL)

name changed to Incannex Healthcare Limited

The suspension of trading in the securities of Impression Healthcare Limited will be lifted immediately following the release by IHL of an announcement regarding a material supply agreement.

The company has officially launched its wholly owned novel cannabinoid drug discovery brand Incannex Pharmaceuticals. Incannex has engaged Linnea SA to be their supply partner for base cannabinoid materials for two of its four novel cannabinoid formulations under design - TMJ Disorder and TBI/Concussion. Incannex by Impression's four areas of cannabinoid research and imminent clinical trials include: Obstructive Sleep Apnoea, Traumatic Brain Injury (TBI)/Concussion, Temporomandibular Joint (TMJ) Disorder and Periodontitis (Gum Disease) and Gingivitis. IHL under the Incannex brand has also launched a line of EU GMP-approved pharmaceutical grade CBD Oil products to treat conditions prevoiusly approved for treatment with cannabinoids under Special Access Scheme. These Incannex Oils can be sold under Australia's largest distribution network "“ Cannvalate - on a non-exclusive basis. TGA Special Access Scheme Category B Sales for medicinal cannabis products have increased 229% from 670 approvals in January of 2019 to 2206 approvals in July of 2019.

The securities of Impression Healthcare Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of IHL, pending the release of an announcement regarding a material supply agreement.

The suspension of trading in the securities of Impression Healthcare Limited will be lifted immediately, following the release by IHL of an announcement regarding its application to the Federal Court of Australia seeking declaratory relief and ancillary orders relating to prior trading in its securities.

The company's application was heard at 10.15 am on 20 May 2019. The Federal Court has made the orders, and pursuant to these orders, any person who claims to have suffered substantial injustice or is likely to suffer substantial injustice by the making of the orders has liberty to apply to vary or to discharge the orders within 60 days from the date of this announcement and the reinstatement of the company's securities by the ASX .

The company has become aware that a number of share and option issues made over the past few years were, in erorr, not accompanied by the issue of a cleansing prospectus. The company has filed an application with the Federal Court of Australia seeking declaratory relief and ancillary orders under the Corporations Act to validate prior trading in shares and options issued under the Prior Securities Issues, and relieve persons who have sold those shares and options without further disclosure from any civil liability they may otherwise have. The application will be heard by the Federal Court at 10.15 am on Monday, 20 May 2019.

The company has lodged a cleansing prospectus to cleanse all relevant shares and options so that subsequent trading of the company's shares and options is not subject to secondary trading restrictions. The Company is also preparing an application to the Federal Court of Australia seeking declaratory relief and ancillary orders to validate prior trading in shares and options issued under the Prior Securities Issues, and relieve persons who have sold those shares and options without further disclosure from any civil liability they may otherwise have. The Company currently expects to file this application early in the week beginning 13 May 2019.

The company issues a cleansing prospectus for an offer of up to 10,000 New Shares at an issue price of $0.02 per New Share (together with one free attaching New Option for every one (1) New Share subscribed for and issued) to raise up to $200.

The securities of Impression Healthcare Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of IHL, pending the release of an announcement regarding its application to the Federal Court of Australia seeking declaratory relief and ancillary orders relating to prior trading in its securities.

The suspension of trading in the securities of Impression Healthcare Limited will be lifted immediately, following the release of an announcement.

Impression secures letter of intent and exclusivity agreement with leading US-based cannabinoid biotechnology and pharmaceutical company, AXIM Biotechnologies Incorporated. The LOI considers the opportunity for Impression to license and distribute AXIM's current and future range of cannabinoid-based products for distribution by Impression in Australia and New Zealand, subject to regulatory approval. The relationship represents Impression's commitment to innovation and disruption within the oral health sector, the healthcare sector more broadly, and affords Impression the opportunity to license innovative and exciting cannabinoid products. AXIM is focused on research, development and production of oral health, pharmaceutical, nutraceutical and cosmetic products incorporating cannabinoids and has established a full chain of production, including extraction, purification, conversion and microencapsulation. Impression has engaged reputable Melbourne-based consulting firm, Pharmout specialising in cannabinoids to advise it on regulatory and other matters related to AXIM's products.

The company has executed a capital raise mandate with Alignment Capital Pty Ltd to raise a total of $2.2m by way of three separate funding initiatives: an entitlement-based Rights Issue by way of prospectus; a post-Rights Issue placement; and $750,000 via a fully subscribed converting loan offer.

The securities of Impression Healthcare Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of IHL, pending the release of an announcement.

The securities of Impression Healthcare Limited will be reinstated to quotation immediately, following the release of an announcement by the Company.

The company has received firm commitments to place 48,453,450 fully paid ordinary shares at $0.025 to raise $1,211,336 before costs. Placement funds will primarily be allocated to marketing and promotional activities to accelerate sales growth as the Company works towards achieving break-even and profitability.

The securities of Impression Healthcare Limited will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company

The securities of the Company will be reinstated to Official Quotation from the commencement of trading on Tuesday 22 November 2016, following the Company's compliance with Listing Rule 11.1.3 and Chapters 1 and 2 of the ASX Listing Rules.

name changed from Mount Magnet South Limited